Because SP (including NAA, HP and MMD) were always considered benign polyps, the adjusted specificities with SP counted as normal for methylated SEPT9 alone, methylated SDC2 alone, and ColoDefense test were 92.6% (95% CI: 88.4%‐95.4%), 93.4% (95% CI: 89.4%‐95.3%), and 87.7% (95% CI: 82.8%‐91.4%), respectively. This evidence concerns the gene SEPTIN9 and multiminicore myopathy.